Condition: Duchenne Muscular Dystrophy · Duchenne Disease · Muscular Dystrophy · Sponsor: University of Florida
Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.
This description comes directly from the study's public registry record.
Tanja Taivassalo, Ph.D. · 352-294-8748 · ttaivassalo@ufl.edu
Ruby Sullivan, MS · 352-294-5392 · r.sullivan1@ufl.edu
Always discuss trial participation with your own doctor first.
| University of Florida Clinical and Translational Research Building | Gainesville, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06290713